dgat1 in 1

DGAT1-IN-1是 DGAT1的高效抑制剂，在 Hep3B 细胞过表达 DGAT1裂解物中，测得IC50低于10nM。

Pradigastat (LCQ-908) 是一种具有口服活性、有效性和选择性的二酰基甘油酰基转移酶 1 (DGAT1) 抑制剂，可用于治疗便秘，可用于研究肥胖和糖尿病。

AZD7687 is a potent and selective DGAT1 inhibitor with an IC50 value of 80 nM (hDGAT1). IC50 value: 80 nM [1] Target: DGAT1 in vitro: Plasma AZD7687 exposure was measured repeatedly. AZD7687 markedly reduced postprandial TAG excursion with a steep concent

T863 (DGAT-3) 是口服有效的二酰基甘油酰基转移酶1 选择性抑制剂。T863结合DGAT1的酰基辅酶A 结合位点，抑制三酰甘油在细胞内的合成。

DGAT1-IN-3 是一种选择性的、有效的，口服具有活力的 DGAT-1 抑制剂，能够抑制人类 DGAT-1 (IC50: 38 nM) 和大鼠 DGAT-1 (IC50: 120 nM)。DGAT1-IN-3 能够用于肥胖、血脂异常和代谢综合征的研究。

ALN29882 is a glycerolipid, that is located at the plasma membrane. It is made up of two fatty acid chains that are covalently attached to a single glycerol molecule with the help of an ester linkage. 18:1 DG has been used as a diacyl-glycerol source in diacylglycerol O-acyltransferase 1 (DGAT1) assay. It has also been used as substrate to assess compounds as potential inhibitors of DGAT-1 in DGAT-1 enzyme assay. It is suitable to use in lipid-protein overlay screen assay with the recombinant protein His-AtROP6.